Geode Capital Management LLC Purchases 52,362 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Geode Capital Management LLC lifted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 7.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 714,956 shares of the company's stock after purchasing an additional 52,362 shares during the period. Geode Capital Management LLC owned 1.36% of Janux Therapeutics worth $38,288,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Y Intercept Hong Kong Ltd bought a new stake in shares of Janux Therapeutics during the third quarter worth approximately $317,000. Barclays PLC grew its stake in shares of Janux Therapeutics by 496.5% during the third quarter. Barclays PLC now owns 174,061 shares of the company's stock worth $7,907,000 after purchasing an additional 144,883 shares during the period. Virtu Financial LLC increased its holdings in Janux Therapeutics by 48.0% in the third quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock valued at $339,000 after purchasing an additional 2,419 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Janux Therapeutics by 64.5% during the third quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock worth $937,000 after buying an additional 7,442 shares during the last quarter. Finally, Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at approximately $139,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the sale, the insider now directly owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. This represents a 3.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock in a transaction dated Wednesday, March 5th. The stock was acquired at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 29.40% of the company's stock.

Janux Therapeutics Price Performance

Shares of JANX stock traded up $1.00 on Friday, hitting $29.69. 367,166 shares of the company's stock were exchanged, compared to its average volume of 852,291. Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.71. The company has a 50 day moving average of $30.80 and a 200 day moving average of $43.70. The stock has a market cap of $1.75 billion, a P/E ratio of -25.38 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on JANX shares. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. Scotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday, February 28th. Wedbush reiterated an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Lifesci Capital upgraded shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.